# A Phase 1 Study to Assess the Safety, Tolerability and PK of IV TP-271

> **NCT02724085** · PHASE1 · COMPLETED · sponsor: **Tetraphase Pharmaceuticals, Inc** · enrollment: 57 (actual)

## Conditions studied

- Pneumonia

## Interventions

- **DRUG:** TP-271

## Key facts

- **NCT ID:** NCT02724085
- **Lead sponsor:** Tetraphase Pharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12-18
- **Primary completion:** 2016-09-28
- **Final completion:** 2016-12-12
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2021-12-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02724085

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02724085, "A Phase 1 Study to Assess the Safety, Tolerability and PK of IV TP-271". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02724085. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*